The Therapeutics Development Network Coordinating Center partners with the Investigational Drug Service at Seattle Children's Hospital to provide pharmacy-related support for multi-center CF clinical studies.
Site Search
The strength of the Therapeutics Development Network Coordinating Center lies in our unparalleled experience in setting up and managing cystic fibrosis studies and our intimate knowledge of the CF research community.
To address the unique and emerging needs of people with cystic fibrosis, the Cystic Fibrosis Foundation has established a research working group to identify knowledge gaps, determine research priorities, and develop the infrastructure needed to conduct the research related to sexual, reproductive, and gender health.
The primary responsibility of the independent Data
Effective clinical development plans and good study design can save sponsors and investigators time and money, leading to faster development of potential new therapies for people with cystic fibrosis.
The Therapeutics Development Network includes over 90
Therapeutics Development Network investigators and research staff work every day to promote quality,
Access to antimicrobial tools can aid researchers in the discovery of new anti-infective treatments for cystic fibrosis.
Germs can spread in a number of ways, but the most common are by direct and indirect contact and through the air.
MRSA stands for methicillin-resistant Staphylococcus aureus. The bacteria can cause an infection on the skin and in the lungs. It is resistant to several common antibiotics. But MRSA can be treated with some antibiotics, nose drops, and other therapies.